UltraThera is developing therapeutic ultrasound to restore brain function, with Alzheimer’s disease as the lead indication. We are at an early clinical stage with proof-of-concept safety using our 1st generation portable and non-invasive system. Current Alzheimer’s therapies are limited in efficacy because they only target a single mechanism of action. We have developed a therapy that targets toxic amyloid and toxic tau, as well as restoring memory and other brain functions as shown by our extensive preclinical data. UltraThera is seeking investment to continue its development program.
Visit Company Website
